Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: Randomised trial

• Published in: Clinical nutrition (Edinburgh, Scotland) Scotland), 2014-12, Vol.33 (6), p.1017-1023
• Main Authors: Sánchez-Lara, Karla, Turcott, Jenny G, Juárez-Hernández, Eva, Nuñez-Valencia, Carolina, Villanueva, Geraldine, Guevara, Patricia, De la Torre-Vallejo, Martha, Mohar, Alejandro, Arrieta, Oscar
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Appetite - drug effects; Biological and medical sciences; Body Composition - drug effects; Body Weight - drug effects; Carboplatin - therapeutic use; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Cisplatin - therapeutic use; Dietary Supplements; Eicosapentaenoic acid; Eicosapentaenoic Acid - administration & dosage; Energy Intake; Feeding. Feeding behavior; Female; Fundamental and applied biological sciences. Psychology; Gastroenterology and Hepatology; Health-related quality of life; Humans; Male; Medical sciences; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Non-small cell lung cancer; Nutritional Status; Pneumology; Prognosis; Quality of Life; Treatment Outcome; Tumors; Tumors of the respiratory system and mediastinum; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Young Adult
• ISSN: 0261-5614; 1532-1983
• DOI: 10.1016/j.clnu.2014.03.006

Summary Background Nutritional interventions have shown increased energy intake but not improvement in health-related quality of life (HRQL) or prognosis in non small cell lung cancer (NSCLC) patients. Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects. Objective To compare the effect of an oral EPA enriched supplement with an isocaloric diet on nutritional, clinical and inflammatory parameters and HRQL in advanced NSCLC patients. Design Patients with advanced NSCLC were randomized to receive diet plus oral nutritional supplement containing EPA (ONS-EPA) or only isocaloric diet (C). All patients received paclitaxel and cisplatin/carboplatin treatment. Weight, body composition, dietary intake, inflammatory parameters and HRQL were assessed at baseline and after the first and second cycles of chemotherapy. Response to chemotherapy and survival were evaluated. Results Ninety two patients were analysed (46 ONS-EPA,46 C). ONS-EPA group had significantly greater energy ( p